Publications
Archives
Globe D, Glidden D, Hertel J, Thomas J, Ackerman M, Chidolue F, Blanco B, Borden A, Goss TF, Xu X, & Kewalramani R (2007). Assessment of the Impact of Weekly Versus Monthly Erythropoiesis Stimulating Protein Therapy on Patients with Chronic Kidney Disease and Their Families. Nephrology Nursing Journal. 34(2), 151-61.
Ferrara, JV (2007). Personalized Medicine: Challenging Pharmaceutical and Diagnostic Company Business Models. McGill Journal of Medicine. 10(1).
Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monès J, Xu X, Zlateva G, Buggage R, Conlon J, & Goss TF (2007). Burden and Resource Utilization of Neovascular AMD: Findings of a Multi-country Study. Archives of Ophthalmology. 125(9), 1249-1254.
A Guide to US Reimbursement for Drugs, Medical Devices, and Diagnostics, D&MD Publications, March 2006.
Bernardo M, Crawford P, Hertel J, Sholer C, Xu X, Goss TF, Kewalramani R, & Globe D (2006). Assessment of Time and Practice Resources Required to Provide Weekly or Monthly Erythropoiesis Stimulating Protein Therapy to Chronic Kidney Disease Patients in the Physician Office Setting. Journal of Managed Care Pharmacy. 12(9), 714-725.
Buggage RR, Xu X, Cruess AF, Zlateva G, Knight T, & Goss TF (2006). Clinical Characteristics and Impact of Neovascular Age-Related Macular Degeneration on Medical Status, Daily Living, Functioning, and Health Resource Utilization: A Survey of Five Countries. Investigative Ophthalmology & Visual Science. 47(E-Abstract 2208).
Cruess AF, Xu X, Monès J, Lotery A, Pauleikhoff D, Soubrane G, Zlateva G, & Goss TF (2006). Humanistic Burden and Health Resource Utilization Among Neovascular Age-Related Macular Degeneration (AMD) Patients: Results from a Multi-Country Cross-Sectional Study. Investigative Ophthalmology & Visual Science. 47(E-Abstract 2199).
Ferrara, JV (2006, March). Personalized Medicine: Challenges in Assessing and Capturing Value in the Commercial Environment. Expert Review of Molecular Diagnostics, Future Drugs, Ltd. 6(2).
Marotta CA, Scharf J, Mafilios MS, Knight T, Parker GD, Matchar D, Samsa D, & Goss TF (2006). Impact of Length of Stay and Costs on the Ability of Hospitals to Adopt New Technology for the Treatment of Acute Ischemic Stroke Patients. Stroke. 37, 711.
Matchar D, Goss TF, Samsa GP, & Marotta CA (2006). An Examination of Patterns of 12-month Medicare Reimbursement for Patients Hospitalized with Ischemic or Hemorrhagic Stroke in 1991 vs 2000. Stroke. 37, 712.
Robbertz A, Lauf R, Rupp R, & Alexander D (2006, September/October). A Qualitative Assessment of Dental Care Access and Utilization among the Older Adult Population in the United States. AGD General Dentistry. 54(5).
Thomas J, Ackerman M, Borden A, Xu X, Goss TF, Kewalramani R, & Globe D (2006). Comparison of Practice Resource Use and Patient Burden for Weekly (QW) Compared to Monthly (QM) Erythropoiesis Stimulating Protein (ESP) Therapy. Journal of the American Society of Nephrology. 17, 918A.
Totten P & Goss TF (2006, January/February). The Impact of Payer Coverage and Reimbursement Policies on Off-Label Use of Anticancer Therapies. Oncology Issues. 40-42.
Xu X, Zlateva G, Goss TF, Buggage R, & Cruess A (2006). Impact of Bilateral Neovascular Age-Related Macular Degeneration and Related Visual Impairment on Patients’ Quality of Life and Functioning: A Survey of Five Countries. Value in Health. 9, A371-A372.
2005
Brauer CA, Olchanski NV, Rosen AB, & Neumann PJ (2005). Cost-Utility Analyses in Orthopedic Surgery. American Journal of Bone and Joint Surgery. 87(6), 1253-9.
Clark MA, Olchanski N, & Ciocca R (2005). Hospital Outcomes and Costs after High-Risk Carotid Endarterectomy: Results from a 5-year Medicare Claims Analysis. Circulation. 111, e310-e359.
Goss TF, Mafilios M, Reblando J, Parker G, & Marotta C. Summary of Medical Resource Utilization and Costs Associated with Hospital Inpatient Treatment of Acute Stroke. Stroke. 36, 477.
Neumann PJ, Greenberg D, Olchanski NV, Stone PW, & Rosen AB (2005). Growth and Quality of the Cost-Utility Literature, 1976-2001. Value in Health. 8(1), 3-9.
Neumann PJ, Rosen AB, Greenberg D, Olchanski NV, Pande R, Chapman RH, Stone PW, Ondategui-Parra S, Nadai J, Siegel JE, & Weinstein MC (2005). Can We Better Prioritize Resources for Cost-Utility Research? Medical Decision Making. 25(4), 429-436.
Olchanski N, Clark MA, & Cohen DJ (2005). Inpatient Resource Utilization and Costs of Procedures Implanting Drug-Eluting Stents in Complex Cases: The ARRIVE Registry. Circulation. 111, e310-e359.
Rosen AB, Greenberg D, Stone PW, Olchanski NV, & Neumann PJ (2005). Quality of Abstracts of Papers Reporting Original Cost-Effectiveness Analyses. Medical Decision Making. 25(4), 424-28.
Stone PW, Schackman B, Neukermans CP, Olchanski N, Greenberg D, Rosen A, & Neumann PJ. A Synthesis of Cost-Utility Analysis Literature in Infectious Disease. Lancet Infectious Diseases. 383-391.
Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, & Green RC (2005, March/April). Genetic Testing For Alzheimer's Disease And Its Impact On Insurance Purchasing Behavior. Health Affairs.
Alexander W, Berlin J, Cyr PL, Schofield A, & Platt LA (2004). Realities at the Leading Edge of Research. European Molecular Biology Organization (EMBO) Reports. 5(4), 324-329.
Greenberg D, Rosen AB, Olchanski NV, Stone PW, Nadai J, & Neumann PJ (2004). Delays in Publications of Cost-Utility Analyses Conducted Alongside Clinical Trials: Registry Analysis. British Medical Journal. 328, 1536-1537.
Pirraglia PA, Rosen AB, Hermann RC, Olchanski NV, Neumann PJ (2004). Cost-Utility Analysis Studies of Depression Management: A Systematic Review. American Journal of Psychiatry. 161(12), 2155-2162.
A Guide To Achieving Reimbursement For Medical Devices, Diagnostics, and Pharmaceuticals in the United States, D&MD Publications, July 2003.
Diette GB, Cangialose CB, Knight TG, Yeh YC, Goss TF, Harnett JP, & Wilson J (2003). Long-term Benefits of Antibiotic Treatment in Reducing Recurrence Rates and Resource Utilization in Acute Exacerbations of Chronic Bronchitis (AECB). European Respiratory Journal. 22(45), 560s.
Ferrara, JV (2003 January/February). Is the Current Reimbursement Structure Limiting R&D in IVDs? IVD Technology. 9(1).
Beusterien KM, Plante KM, Waksman R, Raizner AE, Annis M, & Goss TF (2002). The Cost Effectiveness of Beta-Radiation Therapy for Treatment of In-Stent Restenosis: An Analysis at 290 Days Follow-Up. Cardiovascular Radiation Medicine. 3(2), 107-113.
Kanter LJ, Siegel CJ, Snyder CF, Pelletier EM, Buchner DA, Goss TF (2002). Impact of Respiratory Symptoms on Health-Related Quality of Life and Medical Resource Utilization of Patients Treated by Allergy Specialists and Primary Care Providers. Annals of Allergy Asthma and Immunology. 89, 39-147.
Buchner DA, Graboys TB, Johnson K, Mordin MM, Goodman L, Partsch DS, & Goss TF (2001). Development and Validation of the ITG Health-Related Quality-of-Life Short-Form Measure for Use in Patients with Coronary Artery Disease. Clinical Cardiology. 24, 556-563.
Beusterien KM, Buesching DP, Robison RN, Keats MM, Tomlinson JR, Cofran KW, Bailit HW, Adler DA, Bungay KM, Schrammel PN, & Goss TF (2000). Evaluation of an Information Exchange Program for Primary Care Patients with Depression. Disease Management. 3(1), 1-9.
Bukstein DA, McGrath MM, Buchner DA, Landgraf J, & Goss TF (2000, February). Evaluation of a Short Form for Measuring Health-related Quality of Life Among Patients. Journal of Allergy and Clinical Immunology. 105(2 Pt 1), 245-251.
Malkin JD, Pelletier EM, Van Gool R, & Goss TF (2000). Payer Costs of Pancreatic Cancer in a Nonelderly Medicaid Population. Value In Health, 3(5), 354.
Najib MM, Stein GE, & Goss TF (2000). Cost-Effectiveness of Sparfloxacin Compared with Other Oral Antimicrobials in Outpatient Treatment of Community-Acquired Pneumonia. Pharmacotherapy. 20(4), 461-469.
Cyr PL & Malloy D (1999). Patient Satisfaction and Physician Profiling. In Lynam K & Piland N (Eds.) Physician Profiling: A Source Book for Health Care Administrators. (pp 121-136). San Francisco: Jossey-Bass Health Series.
McGrath MM, Bukstein DA, Buchner DA, Guzman GI, Landgraf JM, & Goss TF (1999). Assessment of the Relationship Between Disease Severity and General and Disease-Specific Health-Related Quality of Life in Pediatric Asthma Patients. Ambulatory Child Health. 5, 249-261.
Neylan JF, Sullivan EM, Steinwald B, & Goss TF (1998). Assessment of the Frequency and Costs of Post-Transplant Hospitalizations in Patient Receiving Tacrolimus (FK506) Versus Cyclosporine. American Journal of Kidney Diseases. 32(5), 770-777.
Ware JE, Kemp JP, Buchner DA, Singer AE, Nolop KB, & Goss TF (1998). The Responsiveness of Disease- Specific and Generic Health Measures to Changes in the Severity of Asthma Among Adults. Quality of Life Research. 7(3), 235-244.
Goss TF (1997). Formulary Decision Making Incorporating Humanistic Outcomes. Pharmacoeconomics and Outcomes: Applications for Patient Care. Module 3: Assessment of Humanistic Outcomes. American College of Clinical Pharmacy.
Halm EA, Causino NA, Cyr PL, & Blumenthal D (1997). Physician Ratings of the Effects of Gate Keeping on Cost and Quality of Care. Journal of General Internal Medicine.
Keller SD, Bayliss MS, Damiano AM, Goss TF, Hsu MA, & Ware JE (1997). Comparison of Responses to SF-36 Health Survey Questions with One-Week and Four-Week Recall Periods. Health Services Research. 32(3), 367-384.
Shield CF, McGrath MM, & Goss TF (1997). Assessment of Health-Related Quality of Life in Kidney Transplant Patients Receiving Tacrolimus (FK506) - Based Versus Cyclosporine-Based Immunosuppression. Transplantation. 64(12), 1738-1743.
Stafford RS & Cyr PL (1997). The Impact of Cancer on the Physical Function of the Elderly and their Utilization of Health Care. Cancer. 80, 1973-80.
Amsden GW, Goss TF, Harrison NJ, D'Andrea DT, & Schentag JJ (1994). Pharmacodynamics of Bolus Famotidine Versus Infused Cimetidine, Ranitidine, and Famitidine. Journal of Clinical Pharmacology. 34(12), 1191-1198.
Goss TF, Forrest A, Nix DE, Ballow CH, Birmingham MC, Cumbo TJ, & Schentag JJ (1994). Mathematical Examination of Dual Individualization Principles (II): The Rate of Bacterial Eradication At The Same Area Under The Inhibitory Curve (AUIC) Is More Rapid For Ciprofloxacin Than For Cefmenoxime. Annals of Pharmacotherapy. 28, 863-868.
Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, & Schentag JJ (1993). The Pharmacodynamics of Intravenous Ciprofloxacin In Seriously Ill Patients. Antimicrobial Agents and Chemotherapy. 37(5), 1073-1081.
Goss TF, Sarlo AM, Nix DE, & Schentag JJ (1993). Renal Enzymuria in Subjects Receiving Once-Daily Versus Three Times Daily Gentamicin. Clinical Pharmacology & Therapeutics. 53, 237.
Schentag JJ & Goss TF (1993). Pharmacokinetics and Pharmacodynamics of Acid-suppressive Agents in Patients with Gastroesophageal Reflux Disease. American Journal of Hospital Pharmacy, 50(1), S7-S10.
Goss TF, Walawander CA, Grasela TH, Meisel S, Katona B, & Jaynes K (1992). Prospective Evaluation of Risk Factors for Antibiotic Associated Bleeding in Critically Ill Patients. Pharmacotherapy. 12(4), 283-291.
Goss TF, Birmingham MC, & Zullich SG (1992). Infection in Long-Term Care Patients: The Role of Third Generation Cephalosporins. The Consultant Pharmacist. 7(11), 1172-1181.
Luzier A., Goss TF, Cumbo TJ, & Schentag JJ (1992). Mathematical Examination of Dual Individualization Principles (III): Development of a Scoring System for Pneumonia Staging and Quantitation of Response to Antibiotics: Results in Cefmenoxime Treated Patients. Annals of Pharmacotherapy. 26, 1358-1365.
Schentag JJ & Goss TF (1992). Quinolone Pharmacokinetics in the Elderly. American Journal of Medicine. 92(3A), 365-405.
Goss TF, Piscitelli SC, & Schentag JJ (1991). Evaluation of Ketoconazole Bioavailability Interactions with Sucralfate and Ranitidine using Gastric pH Monitoring. Clinical Pharmacology & Therapeutics. 49(2), 128.